AstraZeneca plc, a British-Swedish multinational pharmaceutical and biotechnology company, has entered into a strategic partnership agreement with China's CSPC Pharmaceuticals Group Limited to develop new oral drugs based on artificial intelligence. This is reported in a press release from AstraZeneca.
As part of the partnership, CSPC will receive an upfront payment of $110 million, revenue of $1.62 billion during the development stages, and $3.6 billion from sales plus royalties. At the same time, AstraZeneca will retain the exclusive rights to the global licensing of all received candidate drugs.
The partnership will focus on the identification and development of preclinical treatments for chronic diseases, including low-molecular-weight oral therapy for immunological diseases. The research will use the CSPC AI platform, which analyzes the interactions of proteins and compounds to optimize potential treatments.
The deal aims to expand AstraZeneca's presence in China after investments made in early 2025 in the amount of $2.5 billion. The research will be conducted at CSPC's facilities in Shijiazhuang (China).
AstraZeneca is a British—Swedish multinational pharmaceutical and biotechnology company engaged in research, production and promotion of medicines. The main research and development centers are located in Cambridge (England), Gaithersburg (Maryland, USA), Melndal (a suburb of Gothenburg, Sweden) and Warsaw (Poland). The headquarters is located in Cambridge (UK).
Read also in our Telegram channel "Mergers and acquisitions. AK&M».
